LoQus23 Therapeutics raises £35m to advance therapy for Huntington’s disease
The proceeds of the financing will support the development of LoQus23’s lead candidate, a small molecule inhibitor that is expected to enter the clinic in 2026.
Archives for October 3, 2024
SK pharmteco to strengthen small molecule and peptide capacity with $260 million investment
SK Group’s contract development and manufacturing organization (CDMO) arm SK pharmteco is spending $260 million to expand its small molecule and peptide manufacturing muscle in South Korea.